RNXT Overview

RenovoRx, Inc. is a clinical and a commercial biopharmaceutical company. Its lead product RenovoCath a local drug delivery device, targeting high unmet medical needs. RenovoRx’s patented Trans-Arterial Micro-Perfusion (TAMP) therapy platform is designed to ensure targeted therapeutic delivery across the arterial wall near the tumor site to bathe the target tumor. RenovoRx’s novel approach to targeted treatment offers the potential for increased safety, tolerance, and improved efficacy, and to transform the lives of cancer patients by providing innovative solutions to enable targeted delivery of diagnostic and therapeutic agents. In addition to the RenovoCath device, RenovoRx is also evaluating the novel Phase III drug-device combination oncology product candidate (intra-arterial gemcitabine, known as IAG). The combination of intra-arterial infusion of chemotherapy, gemcitabine, and the RenovoCath device is being evaluated for the treatment of locally advanced pancreatic cancer.

Wall Street analysts forecast RNXT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RNXT is5.63 USD with a low forecast of 3.00 USD and a high forecast of 12.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

RenovoRx Inc revenue for the last quarter amounts to 563.00K USD, increased 185.79

RenovoRx Inc. EPS for the last quarter amounts to -0.09 USD, increased 12.50

RenovoRx Inc (RNXT) has 17 emplpoyees as of June 24 2026.

Today RNXT has the market capitalization of 41.05M USD.